Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.
Right now, Dynavax Technologies Inc. (NASDAQ: DVAX) share price is at $5.35, after a 5.48% decrease. Over the past month, the stock went up by 57.65%, but over the past year, it actually decreased by 1.29%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.The stock is currently above from its 52 week low by 197.22%. Assuming that all other factors are held constant, this could present itself as an opportunity for investors trying to diversify their portfolio with biotechnology stocks, and capitalize on the lower share price observed over the year.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 1.15 in the biotechnology industry, Dynavax Technologies has a lower P/E ratio of 0.0. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.price to earnings ratio is not always a great indicator of the company's performance. Depending on the earnings makeup of a company, investors may not be able to attain key insights from trailing earnings.See more from Benzinga * 20 Healthcare Stocks Moving In Friday's Pre-Market Session * Price Over Earnings Overview: Dynavax Technologies * 20 Healthcare Stocks Moving In Thursday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The biotech sector remains in focus with pipeline updates on coronavirus treatments.
Substantial progress has been made over the past few weeks with pharmaceutical companies speeding up development of coronavirus vaccines.
If successful, the Sanofi (SNY) and GlaxoSmithKline plc (GSK) vaccine would be available in the second half of 2021. Shares of drugmakers jumped on the news.
Dynavax Technologies (DVAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its previously announced underwritten public offering of 16,100,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,100,000 shares, at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, were approximately $80.5 million. Cowen, Evercore ISI and William Blair acted as joint book-running managers for the offering.
Q1 2020 HEPLISAV-B® net product revenue of $10.5 million, compared to $5.6 million in Q1 2019Multiple collaborations established leveraging Dynavax’s vaccine adjuvant CpG 1018.
EMERYVILLE, Calif., April 23, 2020 -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines,.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced it is donating 10,000 doses of HEPLISAV-B adult vaccine to help protect healthcare professionals on the front lines of the COVID-19 response against hepatitis B, a potentially deadly virus that is spread through contact with infected blood and bodily fluids and can live on surfaces for at least seven days. Direct Relief is administering the donation program on behalf of Dynavax. Interested healthcare providers and facilities throughout the U.S. who are vaccinating surge healthcare workers and hospital staff can visit DirectRelief.org/apply to learn more about accessing the donated vaccine supply of HEPLISAV-B.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, and Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced that they have entered into a collaboration to develop a vaccine to prevent COVID-19. The collaboration will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018 ™.
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common stock being offered in the public offering. All of the shares in the offering will be sold by Dynavax.
Demonstrated seroprotection rate of 86.4% at week 20 after 4 standard doses of HEPLISAV-BSafety data showed HEPLISAV-B was well toleratedCompany to host webinar review of data.
Joining me on the call today are Ryan Spencer, Chief Executive Officer; Michael Ostrach, Chief Financial Officer; Donn Casale, Vice President, Commercial. Before we begin, I advise you that we will be making forward-looking statements today, including statements regarding HEPLISAV-B's commercial profile, revenue expectations, potential peak revenue, the completion of post-marketing studies and regarding vaccine development with CpG-1018.
Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical data releases and regulatory approval decisions, which are arguably far more important metrics for gauging biotechnology firms' long-term prospects.So, how are investors supposed to distinguish between the long-term winners and those poised to take an "L"? We suggest taking a page from the analyst community's playbook.Using TipRanks' database, we were able to scan the densely populated industry for the most compelling plays. These biotech stocks not only have earned overwhelmingly bullish support from the Wall Street analysts who cover them, but sky-high upside based on the pros' estimates. Here are seven of Wall Street's best biotech stocks right now, according to the analyst community, which believes each of these picks has triple-digit return potential. SEE ALSO: Pros' Picks: The 15 Best Nasdaq Stocks You Can Buy
Dynavax Technologies (DVAX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dynavax Technologies (DVAX) is surging 40% in Tuesday’s pre-market trading after revealing that it expects one or more of its collaboration partners will commence a Phase 1 clinical trial of a potential COVID-19 vaccine as soon as July 2020.According to the SEC filing, Dynavax intends to provide an update on its early-stage collaborations in meetings with analysts and investors today.It will discuss the potential development of a vaccine for COVID-19 containing the company’s proprietary toll-like receptor 9 agonist adjuvant CpG-1018 (“CpG-1018”), the adjuvant used in the company’s Heplisav-B product.Heplisav-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. According to Dynavax, 95% of those who received Heplisav-B were protected after just 2 doses in 1 month.“However, there are risks and uncertainties inherent in vaccine research and development, including the timing of completing development, the results of clinical trials, whether the vaccine will be approved for use, the extent of competition, and whether a vaccine can be successfully commercialized” DVAX adds, warning that as a result, its development of a potential COVID-19 vaccine may not be successful.Indeed, HC Wainwright analyst Edward White recently reiterated his Dynavax buy rating with a $12 price target, writing “We do not include any of these COVID-19 collaborations in our valuation, but we view them as an upside option on the recent COVID-19 outbreak.”Instead, he wrote: “We base our $12 price target on our discounted revenue forecasts for Heplisav-B.” This price target indicates 147% upside potential lies ahead. The stock is currently trading down 15% on a year-to-date basis.Overall DVAX has received three recent buy ratings, adding up to a Strong Buy analyst consensus. (See Dynavax stock analysis on TipRanks).Related News: Europe Could Conditionally Approve Gilead’s Remdesivir In Next Few Days Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca Aiming For 30M UK Covid-19 Vaccine Doses By September More recent articles from Smarter Analyst: * Tilray To Shut Ontario Cannabis Greenhouse In Money-Saving Move * Here’s Why Roku Stock Will Stay Afloat * Is CymaBay’s Seladelpar Back in the Saddle? 5-Star Analyst Weighs In * Why Aurora Cannabis (ACB) Stock Looks Attractive
Dynavax Technologies Corporation (DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its previously announced underwritten public offering of 14,000,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds to Dynavax from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Dynavax, are expected to be approximately $70.0 million. In addition, Dynavax has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock.
Shares of the small-cap biotech Dynavax Technologies Corporation (NASDAQ: DVAX) are poised for a big day today. Investors are bidding up Dynavax's shares this morning in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today. One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July.
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.